TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Herreros Villanueva, Marta ^a   Muñiz, Pilar ^b   García Girón, Carlos ^a   Cavia Saiz, Mónica ^a   del Corral, María J C ^a  

^a HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^b UNIVERSITY OF BURGOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; ISOPROTEIN; K RAS PROTEIN; ONCOPROTEIN; OXALIPLATIN; PROTEIN P73; PROTEIN TAP73; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; DNA BINDING PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; PLATINUM COMPLEX; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ARTICLE; CANCER CELL; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; COLORECTAL TUMOR; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; HUMANS; MUTATION; NUCLEAR PROTEINS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS B-RAF; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 77950460159     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-15     Document Type: Article

References (38)

1. Venook AP. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer 2005, 103:2435-2446. 10.1002/cncr.21123, 15880563.
2. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584. 10.1038/nrc2167, 17625587.
3. Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 1994, 57:847-855. 10.1002/ijc.2910570614, 7911457.
4. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997, 90:809-819. 10.1016/S0092-8674(00)80540-1, 9288759.
5. Irwin MS, Kaelin WG. Role of the newer p53 family proteins in malignancy. Apoptosis 2001, 6:17-29. 10.1023/A:1009663809458, 11321038.
6. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002, 18:90-95. 10.1016/S0168-9525(02)02595-7, 11818141.
7. Dominguez G, Garcia JM, Pena C, Silva J, Garcia V, Martinez L, Maximiano C, Gomez ME, Rivera JA, Garcia-Andrade C, Bonilla F. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006, 24:805-815. 10.1200/JCO.2005.02.2350, 16380414.
8. Sun XL, Ouyang XH, Yan MR, Liu GR. p73 expression and its clinical significance in colorectal cancer. Colorectal Dis 2008,
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
10. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004, 55:433-457. 10.1146/annurev.med.55.091902.104433, 14746530.
11. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002, 7(Suppl 4):2-8. 10.1634/theoncologist.7-suppl_4-2, 12202782.
12. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res 2000, 6:747-753.
13. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J, Baselga J. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004, 10:6487-6501. 10.1158/1078-0432.CCR-04-0870, 15475436.
14. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003, 12:541-552. 10.1016/S1097-2765(03)00350-2, 14527402.
15. Hubbard SR. EGF receptor inhibition: attacks on multiple fronts. Cancer Cell 2005, 7:287-288. 10.1016/j.ccr.2005.04.004, 15837615.
16. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7:301-311. 10.1016/j.ccr.2005.03.003, 15837620.
17. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12:5268-5272. 10.1158/1078-0432.CCR-05-1554, 17000658.
18. Bardelli A, Velculescu VE. Mutational analysis of gene families in human cancer. Curr Opin Genet Dev 2005, 15:5-12. 10.1016/j.gde.2004.12.009, 15661527.
19. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004, 10:789-799. 10.1038/nm1087, 15286780.
20. Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytomaa T. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Mol Pathol 2000, 53:24-30. 10.1136/mp.53.1.24, 1186898, 10884918.
21. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001, 85:692-696. 10.1054/bjoc.2001.1964, 2364126, 11531254.
22. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, Peinado MA. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001, 19:299-304.
23. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005, 97:981-989.
24. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007, 67:2643-2648. 10.1158/0008-5472.CAN-06-4158, 17363584.
25. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995. 10.1158/0008-5472.CAN-06-0191, 16618717.
26. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634. 10.1200/JCO.2007.14.7116, 18316791.
27. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712. 10.1200/JCO.2008.18.0786, 19001320.
28. Fernandez-Garcia B, Vaque JP, Herreros-Villanueva M, Marques-Garcia F, Castrillo F, Fernandez-Medarde A, Leon J, Marin MC. p73 cooperates with Ras in the activation of MAP kinase signaling cascade. Cell Death Differ 2007, 14:254-265. 10.1038/sj.cdd.4401945, 16645632.
29. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
30. Morgan DM. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol Biol 1998, 79:179-183.
31. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004, 64:2449-2460. 10.1158/0008-5472.CAN-03-1060, 15059898.
32. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin WG. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 1998, 18:6316-6324. 109218, 9774648.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
34. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108. 10.1038/nprot.2008.73, 18546601.
35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
36. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG. Chemosensitivity linked to p73 function. Cancer Cell 2003, 3:403-410. 10.1016/S1535-6108(03)00078-3, 12726865.
37. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002, 416:560-564. 10.1038/416560a, 11932750.
38. Horvilleur E, Bauer M, Goldschneider D, Mergui X, de la Motte A, Benard J, Douc-Rasy S, Cappellen D. p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res 2008, 36:4222-4232. 10.1093/nar/gkn394, 2490757, 18583365.